605266 Yunnan Jianzhijia Health-Chain
- 47.69
- +1.67+3.63%
Yunnan Jianzhijia Health-Chain News
We Think Jianzhijia Pharmaceutical Chain Group (SHSE:605266) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it might be obvious that you need to consider debt, whe
Jianzhijia (605266): Southwest China and Hebei join forces in diversification to help continue growth
Covered for the first time, an increase in holdings rating is given. The 2023-2025 EPS is expected to be 3.15/3.73/4.44 yuan. The absolute valuation method and relative valuation method are used. According to the principle of prudence, a lower valuation is selected, and the target price is 60
Wang Yanping, the majority shareholder of Jianzhijia (605266.SH), reduced his holdings by 232,000 shares in total, and the reduction period expired
Jianzhijia (605266.SH) issued an announcement. Wang Yanping, the shareholder of the company holding more than 5% of the shares, passed the bidding and trading system...
Jianzhijia Pharmaceutical Chain Group Co., Ltd.'s (SHSE:605266) Most Bullish Insider, CEO Bo Lan Must Be Pleased With the Recent 15% Gain
Key Insights Insiders appear to have a vested interest in Jianzhijia Pharmaceutical Chain Group's growth, as seen by their sizeable ownership A total of 4 investors have a majority stake in the comp
JZJ Chain Drugstore Acquires 69 Pharmacies For 46 Million Yuan
JZJ Chain Drugstore (SHA:605266) has acquired 69 pharmacies from Sichuan Derentang Pharmaceutical Chain for 45.6 million yuan. The pharmacy chain operator expects the move to strengthen its presence i
Jianzhijia (605266.SH) plans to spend 45.6 million yuan to acquire 69 pharmacies in Derentang to strengthen intensive distribution in Chengdu
Zhitong Finance App News, Jianzhijia (605266.SH) announced that its wholly-owned subsidiary, Sichuan Jianzhijia Pharmacy Co., Ltd. (“Sichuan Jianzhijia”), signed a “Pharmacy Asset Acquisition Agreement” with its counterparty Sichuan Derentang Pharmaceutical Chain Co., Ltd. (“Derentang”) to acquire the store assets and operating interests (“target assets”) of 69 pharmacies in Derentang (hereinafter referred to as “target stores”) for 45.6 million yuan. Through the acquisition of target assets this time, Sichuan Jianzhijia has further strengthened its intensive distribution in Chengdu, Sichuan, and entered new regions to achieve rapid distribution and market acquisition
Jianzhijia (605266): Expansion outside the province continues to accelerate omni-channel and diversified operations to bring differentiated competition
Jianzhijia: Upstart pharmacy chain, rapid growth in endogenous+epitaxial two-wheel drive performance. Jianzhijia started in Kunming, Yunnan. After more than ten years of business development, it has a total of 4711 stores in the 6 regions of Yunnan, Sichuan, Guangxi, Chongqing, Hebei and Liaoning
Do Jianzhijia Pharmaceutical Chain Group's (SHSE:605266) Earnings Warrant Your Attention?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. Sometime
Jianzhijia (605266.SH): Shareholder Suzhou and Jurongyi Investment and Coordinating Actors completed a 0.86% reduction in the company's shares
Jianzhijia (605266.SH) announcement. As of the announcement disclosure date, the company's shareholders Suzhou and Jurongyi Investment Partnership...
Jianzhijia Pharmaceutical Chain Group Co., Ltd. (SHSE:605266) Looks Inexpensive But Perhaps Not Attractive Enough
With a price-to-earnings (or "P/E") ratio of 17.9x Jianzhijia Pharmaceutical Chain Group Co., Ltd. (SHSE:605266) may be sending bullish signals at the moment, given that almost half of all companies i
Guojin Securities: The outflow of medical prescriptions is accelerating, and we are optimistic about the strongest companies, Hengqiang
Leading pharmaceutical companies have a higher degree of store compliance and stronger management capabilities. Because they are more supervised and trusted, they are expected to gain a larger share in the process of undertaking the outflow of prescriptions; leading companies have scale effects and are more advantageous in terms of brand, procurement and bargaining power, and logistics management level.
Guojin Securities: The outflow of prescriptions brings incremental space to the industry, optimistic about leading retail pharmacies
Prescription outflow, also known as prescription distribution, refers to the act of patients diagnosing and treating a disease in a hospital. After the doctor prescribes drugs according to the treatment plan, they do not distribute prescriptions at the hospital pharmacy, but choose to distribute prescriptions at social pharmacies.
Jianzhijia (605266.SH): It is expected that next year's store expansion will not be lower than the number of stores expanded in 2023 (about 1000-1100)
On December 13, Gelonghui (605266.SH) said during an on-site visit that the company's annual budget was announced after review and decision by the annual board of directors and shareholders' meetings. In 2024, the company's self-built stores in 2021 and 2022 will gradually cultivate maturity and continue to generate sales and profit contributions; mature stores and online businesses need to continue to improve to achieve endogenous growth; and at the same time, achieve continuous growth in performance through external expansion of “self-build+acquisition”. The company has not yet specified a store expansion plan for next year, but based on the store expansion situation in the past three years and the company's reality, it is expected that the store will expand next year
Jianzhijia (605266.SH): Mobile payment for designated pharmacies is a new development in the company's omni-channel service based on physical pharmacy networks
Gelonghui, December 13|Jianzhijia (605266.SH) said during an on-site visit that the company's regions, such as Shenyang, Liaoning, and Baoshan, Yunnan, are in the pilot phase. In Shenyang, the local health insurance bureau cooperated with Meituan. After spending at the platform's designated pharmacies, customers can use funds from their personal health insurance accounts to pay for products that meet the medical insurance reimbursement criteria. The Baoshan Regional Health Insurance Bureau cooperates with the company's own drug purchase platform. Customers purchase drugs on online shopping malls and place orders. For products that meet medical insurance reimbursement standards, payment can be made using funds from personal health insurance accounts. The company is actively cooperating with the pilot work in Baoshan, Yunnan, and is on the platform
Jianzhijia (605266.SH): There is a certain gap in annual revenue compared to expectations due to market factors and the speed of store expansion
Gelonghui, December 13|Jianzhijia (605266.SH) said during an on-site visit that in the fourth quarter, it has entered the sprint stage of full-year performance. The company grasped the Double Eleven promotion and fall and winter sales opportunities. In October-November, performance recovered in the third quarter, and continued to grow over the same period last year. The number of transactions increased and customer orders declined (including O2O business. After excluding the impact of the rapidly growing O2O business, the unit price of physical store business gradually recovered to the same period). After the epidemic in 2023, the market economy was sluggish. Customers' concerns about future uncertainty affected consumer behavior, and increased attention to the ultimate cost performance ratio
Jianzhijia (605266.SH): 407.888 million restricted shares will be listed and distributed from December 1
Jianzhijia (605266.SH) issued an announcement on the listing and circulation of restricted shares in the initial public offering. This restricted stock listing...
Jianzhijia (605266) Company Information Update Report: Rapid Performance Growth, Diverse Services, Deepening Competitive Advantages
Revenue and profit grew rapidly, maintaining the “buy” rating, and the company released the 2023 three-quarter report: 2023Q1-Q3 achieved revenue of 6.5 billion yuan (+38.03%); net profit of 278 million yuan (+42 million yuan); net profit of 278 million yuan (+42 million yuan).
Jianzhijia (605266): Young store age structure with sufficient growth momentum
Investment Essentials Jianzhijia released its 2023 three-quarter report. In the first three quarters of 2023, the company achieved operating income of 6.5 billion yuan, an increase of 38.03% over the previous year; net profit of the mother was 278 million yuan, an increase of 42.03% over the previous year
CITIC Construction Investment: The pharmacy industry has strong expectations of marginal improvement in operations, and there are allocation opportunities
The operating pace of the pharmacy industry is expected to improve sequentially in '24, and valuations have entered a low level.
Jianzhijia (605266) 2023 Third Quarter Report Review: Steady expansion of stores and rapid growth in performance
Matters: The company released its 2023 three-quarter report. The company's revenue was 6.5 billion yuan (+38.03%), and net profit was 278 million yuan (+42.03%). In the third quarter alone, the company's revenue was 2.162 billion yuan (+
Analysis
Price Target
No Data
